The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10

Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res (2012) 4.91

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 3.46

Overview and findings from the religious orders study. Curr Alzheimer Res (2012) 3.46

3D-CAM: derivation and validation of a 3-minute diagnostic interview for CAM-defined delirium: a cross-sectional diagnostic test study. Ann Intern Med (2014) 3.34

Effect of a 24-Month Physical Activity Intervention vs Health Education on Cognitive Outcomes in Sedentary Older Adults: The LIFE Randomized Trial. JAMA (2015) 3.20

Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83

Contribution of Alzheimer disease to mortality in the United States. Neurology (2014) 2.67

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol (2012) 2.65

Biomarker modeling of Alzheimer's disease. Neuron (2013) 2.51

Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. PLoS Med (2013) 2.49

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement (2014) 2.46

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26

Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol (2015) 2.18

Motoric cognitive risk syndrome and the risk of dementia. J Gerontol A Biol Sci Med Sci (2012) 2.12

Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment. J Am Geriatr Soc (2013) 2.11

Usefulness of data from magnetic resonance imaging to improve prediction of dementia: population based cohort study. BMJ (2015) 2.10

Functional network disruption in the degenerative dementias. Lancet Neurol (2011) 1.98

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol (2014) 1.96

The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.93

Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90

CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement (2013) 1.90

Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia (2012) 1.90

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement (2013) 1.87

Early identification and heritability of mild cognitive impairment. Int J Epidemiol (2013) 1.83

Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain (2015) 1.82

Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med (2014) 1.75

Novel risk markers and long-term outcomes of delirium: the successful aging after elective surgery (SAGES) study design and methods. J Am Med Dir Assoc (2012) 1.73

Random forest-based similarity measures for multi-modal classification of Alzheimer's disease. Neuroimage (2012) 1.71

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol (2012) 1.70

Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol (2013) 1.68

Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol (2012) 1.66

Diagnostic neuroimaging across diseases. Neuroimage (2011) 1.66

Mild cognitive impairment: a concept in evolution. J Intern Med (2014) 1.65

Can performance on daily activities discriminate between older adults with normal cognitive function and those with mild cognitive impairment? J Am Geriatr Soc (2014) 1.65

Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology (2011) 1.63

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol (2012) 1.62

Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging (Albany NY) (2012) 1.61

Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59

In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain (2013) 1.57

Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol (2015) 1.55

Multimodality Review of Amyloid-related Diseases of the Central Nervous System. Radiographics (2016) 1.53

Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol (2013) 1.52

Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement (2013) 1.51

Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51

Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected]. Medicine (Baltimore) (2014) 1.50

DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice. Nat Commun (2015) 1.49

Measuring cognitive change in subjects with prodromal Alzheimer's disease. J Neurol Neurosurg Psychiatry (2013) 1.48

Spectrum of cognition short of dementia: Framingham Heart Study and Mayo Clinic Study of Aging. Neurology (2015) 1.46

Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther (2013) 1.44

Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol (2012) 1.44

Cross-species translation of the Morris maze for Alzheimer's disease. J Clin Invest (2016) 1.43

Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry (2014) 1.42

Suspected early dementia. BMJ (2011) 1.41

Instrumental activities of daily living performance and role satisfaction in people with and without mild cognitive impairment: a pilot project. Am J Occup Ther (2015) 1.40

Comparison of neuropsychiatric symptoms and diffusion tensor imaging correlates among patients with subcortical ischemic vascular disease and Alzheimer's disease. BMC Neurol (2017) 1.39

Slaying dementia dragons with blood, lungs, and guts. J Am Geriatr Soc (2013) 1.39

Application and Revision of Montreal Cognitive Assessment in China's Military Retirees with Mild Cognitive Impairment. PLoS One (2016) 1.39

Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J (2012) 1.39

Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.38

Brain aging, Alzheimer's disease, and mitochondria. Biochim Biophys Acta (2011) 1.36

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. Brain (2014) 1.36

Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology (2012) 1.34

The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta (2013) 1.34

Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain (2015) 1.31

Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology (2014) 1.31

Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology (2012) 1.31

Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. J Alzheimers Dis (2014) 1.30

Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Arch Neurol (2012) 1.29

Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu Rev Clin Psychol (2013) 1.28

Sleep quality and 1-year incident cognitive impairment in community-dwelling older adults. Sleep (2012) 1.27

Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol (2013) 1.26

Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci (2015) 1.26

The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci (2013) 1.26

Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.25

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain (2016) 1.25

The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction. JAMA Neurol (2013) 1.25

Advances in the prevention of Alzheimer's disease and dementia. J Intern Med (2014) 1.23

Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol (2015) 1.23

Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE study. Alzheimers Res Ther (2015) 1.22

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin (2013) 1.21

Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology (2011) 1.21

Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord (2014) 1.21

Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid Redox Signal (2011) 1.21

Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol (2011) 1.20

Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. J Neurol (2012) 1.20

Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. JAMA Neurol (2013) 1.20

Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging (2012) 1.19

Improving dementia care: the role of screening and detection of cognitive impairment. Alzheimers Dement (2013) 1.19

Mild cognitive impairment in Parkinson's disease. Minerva Med (2011) 1.19

[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2013) 1.19

Mouse models of Alzheimer's disease. Brain Res Bull (2011) 1.19

Emergence of mild cognitive impairment in late middle-aged adults in the wisconsin registry for Alzheimer's prevention. Dement Geriatr Cogn Disord (2014) 1.19

The source of cognitive complaints predicts diagnostic conversion differentially among nondemented older adults. Alzheimers Dement (2013) 1.18

The diagnosis and management of mild cognitive impairment: a clinical review. JAMA (2014) 1.18

Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06

Mild cognitive impairment as a diagnostic entity. J Intern Med (2004) 26.95

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62

Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 6.84

Neuropathologic substrate of mild cognitive impairment. Arch Neurol (2006) 6.26

Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20

CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 6.12

Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology (2005) 5.76

The genetics of Alzheimer disease: back to the future. Neuron (2010) 4.91

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55

Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry (2006) 3.22

Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am (2003) 2.43

Structural magnetic resonance imaging in established and prodromal Alzheimer disease: a review. Alzheimer Dis Assoc Disord (2003) 2.12

Defining molecular targets to prevent Alzheimer disease. Arch Neurol (2005) 2.02

Early Alzheimer's disease genetics. J Alzheimers Dis (2006) 1.66

Positron emission tomography and magnetic resonance imaging in the diagnosis and prediction of dementia. Alzheimers Dement (2006) 0.91

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62

The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42

Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14

Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 11.59

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21

Mild cognitive impairment. Lancet (2006) 10.21

Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90

The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64

Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23

Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74

Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (2008) 7.95

Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56

Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron (2005) 7.53

The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2010) 7.15

National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke (2006) 6.94

Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92

Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature (2008) 6.89

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 6.84

Automatic classification of MR scans in Alzheimer's disease. Brain (2008) 6.71

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50

A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab (2005) 6.25

Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00

The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology (2008) 5.94

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89

Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2006) 5.58

The role of apolipoprotein E in Alzheimer's disease. Neuron (2009) 5.55

Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55

Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52

Health economics and the value of therapy in Alzheimer's disease. Alzheimers Dement (2007) 5.52

Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci (2011) 5.40

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10

Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med (2005) 5.10

Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09

Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01

In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci (2003) 5.00

Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science (2009) 4.92

Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85

Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol (2003) 4.82

Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet (2006) 4.80

ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75

Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71

Chronic traumatic encephalopathy in a National Football League player. Neurosurgery (2005) 4.67

Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol (2009) 4.59

The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59

Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55

Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation (2003) 4.52

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature (2009) 4.43

Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage (2007) 4.41

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39

Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25

ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron (2004) 4.21

Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol (2006) 4.19

Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol (2008) 4.15